Role of thrombin-activatable fibrinolysis inhibitor in bronchial asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 461s Year: 2005
Intraalveolar levels of tenascin C and thrombin-activatable fibrinolysis inhibitor in interstitial lung diseases Source: Eur Respir J 2003; 22: Suppl. 45, 83s Year: 2003
Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation Source: Eur Respir J 2007; 30: 423-428 Year: 2007
Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002
Antithrombin plus alpha–1 protease inhibitor does not affect pulmonary inflammation and coagulation in a ‘double-hit’ lung injury model Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018
Effect of curcumin on LPS-induced neutrophil activation and acute lung injury Source: Annual Congress 2012 - Lung injury, respiratory muscles and mechanical ventilation Year: 2012
Effect of neutrophil elastase inhibitor (ONO-5046) and gabexate mesilate on acid-induced lung injury in rats Source: Eur Respir J 2006; 28: Suppl. 50, 660s Year: 2006
Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) by lung cancer cell lines Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002
Inhibition of neutrophil elastase contributes to attenuationof lipopolysaccharide-induced acute lung injuryduring neutropenia recovery in mice Source: International Congress 2017 – Anti-inflammatory and pro-repair mediators in acute lung injury Year: 2017
Role of eNOS in ischemia/reperfusion-induced lung injury Source: Eur Respir J 2007; 30: Suppl. 51, 293s Year: 2007
Ghrelin attenuates lipopolysaccharide-induced acute lung injury Source: Eur Respir J 2005; 26: Suppl. 49, 731s Year: 2005
Inhibition of neutrophil apoptosis by sphingosin-1-phopsphate through the activation of neutral sphingomyelinase in acute lung injury Source: Annual Congress 2010 - Emerging mechanisms in lung injury Year: 2010
Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008
sGC activator BAY 412272 attenuates ischemia/reperfusion injury of the lung Source: Eur Respir J 2006; 28: Suppl. 50, 822s Year: 2006
Effect of phosphodiesterase-4 inhibitor on the inflammation, oxidative damage and apoptosis in a saline lavage-induced model of acute lung injury Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Neutrophil elastase inhibitor sivelestat ameliorates gefitinib, naphthalene-induced acute pneumonitis in mice Source: International Congress 2015 – Novel insights into the pathobiology of acute lung injury Year: 2015
Usefulness of a selective neutrophil elastase inhibitor and a recombinant human soluble thrombomodulin in patients with ARDS and DIC Source: Annual Congress 2013 –Acute respiratory failure, ARDS and severe COPD exacerbations Year: 2013
Pioglitazone attenuates endotoxin-induced acute lung injury by reducing neutrophil recruitment Source: Eur Respir J 2012; 40: 416-423 Year: 2012